Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Estrogen Replacement Therapy and Fractures in Older Women
Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., Cummings, S. R., & and For The Study of Osteoporotic Fractures Research Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 809
Serum vitamin D concentrations among elderly people in Europe
van der Wielen, R. P. J., de Groot, L. C. P. G. M., van Staveren, W. A., Löwik, M. R. H., van den Berg, H., Haller, J., & Moreiras, O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91266-5 · Cited by 772
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Self-citationGenant, H. K., Grampp, S., Glüer, C. C., Faulkner, K. G., Jergas, M., Engelke, K., Hagiwara, S., & van Kuijk, C. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091002 · Cited by 610
Cited by
Items 301–400 of 1,002
Delmas, P. D., RIZZOLI, R. E., Cooper, C. C., & Reginster, J. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1813-0 · Cited by 95
Self-citationPreventing osteoporosis: outcomes of the Australian Fracture Prevention Summit
Carey, R. P. L., Plehwe, W. E., & Ebeling, P. R. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04717.x · Cited by 94
An overview on the treatment of postmenopausal osteoporosis
Maeda, S. S., & Lazaretti‐Castro, M. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003039 · Cited by 94
Ebeling, P. R., Daly, R. M., Kerr, D. A., & Kimlin, M. G. (2013) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2013.tb04225.x · Cited by 94
A Comprehensive Review on Postmenopausal Osteoporosis in Women
Charde, S. H., Joshi, A., & Raut, J. M. (2023) · Cureus · doi:10.7759/cureus.48582 · Cited by 93
Bock, O., & Felsenberg, D. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2134 · Cited by 93
Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover
Eastell, R., Hannon, R. A., Wenderoth, D., Rodríguez, J., & Sawicki, A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0412 · Cited by 93
Self-citationMcClung, M. R. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00079-8 · Cited by 93
Eastell, R., Vrijens, B., Cahall, D. L., Ringe, J. D., Garnero, P., & Watts, N. B. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.342 · Cited by 92
Self-citationBisphosphonates, Old Friends of Bones and New Trends in Clinics
Barbosa, J. S., Paz, F. A. A., & Braga, S. S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01292 · Cited by 91
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old
Fuggle, N. R., Laslop, A., Rizzoli, R., Al‐Daghri, N. M., Alokail, M. S., Bałkowiec-Iskra, E., Beaudart, C., Bruyère, O., Bemden, A. B., Burlet, N., et al. (2025) · Drugs · doi:10.1007/s40265-024-02138-w · Cited by 91
Self-citationWells, G. A., Hsieh, S., Zheng, C., Peterson, J., Liu, W., Kelly, S., & Tugwell, P. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004523.pub4 · Cited by 91
Kanis, J. A., Borgström, F., Johnell, O., & Jönsson, B. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1643-0 · Cited by 91
Vitamin K to prevent fractures in older women: systematic review and economic evaluation
Stevenson, M., Lloyd-Jones, M., & Papaioannou, D. (2009) · Health Technology Assessment · doi:10.3310/hta13450 · Cited by 90
Anti-Hip Fracture Efficacy of Bisphosphonates: A Bayesian Analysis of Clinical Trials
Nguyen, N. D., Eisman, J. A., & Nguyen, T. V. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050903 · Cited by 90
FRAX and fracture prediction without bone mineral density
Kanis, J. A., Harvey, N. C., Johansson, H., Odén, A., Leslie, W. D., & McCloskey, E. V. (2015) · Climacteric · doi:10.3109/13697137.2015.1092342 · Cited by 90
Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2011.05.013 · Cited by 90
Brumsen, C., Papapoulos, S. E., Lips, P. T. A. M., Geelhoed-Duijvestijn, P. H. L. M., Hamdy, N. A. T., Landman, J. O., McCloskey, E. V., Netelenbos, J. C., Pauwels, E. K. J., Roos, J. C., et al. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.1057 · Cited by 89
Ringe, J. D., & Möller, G. (2009) · Rheumatology International · doi:10.1007/s00296-009-0940-5 · Cited by 88
Mitchell, D. Y., Barr, W. H., Eusebio, R. A., Pallone, K. A., Duke, F. P., Russell, D. A., Nesbitt, J. D., Powell, J. H., & Thompson, G. A. (2001) · Pharmaceutical Research · doi:10.1023/a:1011024200280 · Cited by 88
Zhou, J., Ma, X., Wang, T., & Zhai, S. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3654-z · Cited by 88
Willing, M. C., Torner, J. C., Burns, T. L., Janz, K. F., Marshall, T. A., Gilmore, J. M. E., Deschenes, S. P., Warren, J. J., & Levy, S. M. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1416-1 · Cited by 88
Harris, S. T., Watts, N. B., Li, Z., Chines, A. A., Hanley, D. A., & Brown, J. P. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003566 · Cited by 88
Gregorio, S. D., del Río, L., Tolrà, J. R., Bonel, E., García, M., & Winzenrieth, R. (2015) · Bone · doi:10.1016/j.bone.2014.12.062 · Cited by 87
Diagnosis and management of osteoporosis in the older senior
Vondracek, S. F., & Linnebur, S. A. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4965 · Cited by 87
Cheung, A. M., Feig, D. S., Kapral, M., Diaz-Granados, N., & Dodin, S. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1030757 · Cited by 87
A Review of Osteoporosis in the Older Adult
Alejandro, P., & Constantinescu, F. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.03.004 · Cited by 87
Gold, D. T., Safi, W., & Trinh, H. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x154042 · Cited by 87
Gleeson, T., Iversen, M. D., Avorn, J., Brookhart, A. M., Katz, J. N., Losina, E., May, F. W., Patrick, A. R., Shrank, W. H., & Solomon, D. H. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0976-0 · Cited by 86
Multinational survey of osteoporotic fracture management
Dreinhöfer, K., Anderson, M. H., Féron, J.-M., Herrera, A., Hube, R., Johnell, O., Lidgren, L., Miles, K., Tarantino, U., Simpson, H., et al. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1700-8 · Cited by 86
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence
Rabenda, V., Hiligsmann, M., & Reginster, J. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903140533 · Cited by 84
Self-citationOsteoporosis and Skeletal Fractures
Gardner, M. J., Demetrakopoulos, D., Shindle, M. K., Griffith, M. H., & Lane, J. M. (2006) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-005-0137-8 · Cited by 83
Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper, M., Luckey, M. M., McClung, M. R., Pessah‐Pollack, R., et al. (2010) · Endocrine Practice · doi:10.4158/ep.16.6.1016 · Cited by 83
Davis, S., James, M. M., Sanderson, J., Stevens, J., Goka, E., Rawdin, A., Sadler, S., Wong, R., Campbell, F., Stevenson, M., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20780 · Cited by 83
Ste‐Marie, L., Sod, E. W., Johnson, T. D., & Chines, A. A. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0039-7 · Cited by 82
Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women
Heaney, R. P., Zizic, T. M., Fogelman, I., Olszynski, W. P., Geusens, P., Kasibhatla, C., Alsayed, N., Isaia, G., Davie, M. W. J., & Chesnut, C. H. (2002) · Osteoporosis International · doi:10.1007/s001980200061 · Cited by 82
Harris, S. T., Reginster, J., Harley, C., Blumentals, W. A., Poston, S. A., Barr, C. E., & Silverman, S. L. (2009) · Bone · doi:10.1016/j.bone.2009.01.002 · Cited by 81
Self-citationFratzl, P., Roschger, P., Fratzl‐Zelman, N., Paschalis, E. P., Phipps, R. J., & Klaushofer, K. (2007) · Calcified Tissue International · doi:10.1007/s00223-007-9039-8 · Cited by 81
Treatment of Osteoporosis with Bisphosphonates
Watts, N. B. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70194-0 · Cited by 81
How useful are measures of BMD and bone turnover?
Miller, P. D., Hochberg, M. C., Wehren, L. E., Ross, P. D., & Wasnich, R. D. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x41390 · Cited by 80
Reid, I. R., Eastell, R., Fogelman, I., Adachi, J. D., Rosen, A., Netelenbos, C., Watts, N. B., Seeman, E., Ciaccia, A. V., & Draper, M. W. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.8.871 · Cited by 79
Self-citationManagement of osteoporosis in the elderly
Rizzoli, R., Bruyere, O., Cannata-Andia, J. B., Devogelaer, J.-P., Lyritis, G., Ringe, J. D., Vellas, B., & Reginster, J.-Y. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903169262 · Cited by 78
Self-citationManagement of Osteoporosis among the Elderly with Other Chronic Medical Conditions
Curtis, J. R., & Safford, M. M. (2012) · Drugs & Aging · doi:10.2165/11599620-000000000-00000 · Cited by 78
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
Siris, E. S., Simon, J. A., Barton, I. P., McClung, M. R., & Grauer, A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0493-y · Cited by 78
Sanderson, J., Martyn-St James, M., Stevens, J., Goka, E., Wong, R., Campbell, F., Selby, P., Gittoes, N., & Davis, S. (2016) · Bone · doi:10.1016/j.bone.2016.05.013 · Cited by 77
Fleurence, R., Iglesias, C. P., & Johnson, J. M. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725110-00003 · Cited by 77
Prevention, Screening, and Management of Osteoporosis: An Overview of the Current Strategies
Bonura, F. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.07.2021 · Cited by 77
Zhao, G., Liu, X., & Li, F. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3610-y · Cited by 77
Risedronate: A Review of its Pharmacological Properties and Clinical Use in Resorptive Bone Disease
Dunn, C. J., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161050-00013 · Cited by 77
Lanza, F. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02051-7 · Cited by 75
Is bone quality associated with collagen age?
Leeming, D. J., Henriksen, K., Byrjalsen, I., Qvist, P., Madsen, S. H., Garnero, P., & Karsdal, M. A. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0904-3 · Cited by 75
Osteoporosis postmenopáusica. Guía de práctica clínica
(SEIOMM), G. D. T. D. L. S. E. D. I. Ó. Y. M. M. (2003) · Revista Clínica Española · doi:10.1016/s0014-2565(03)71338-1 · Cited by 75
Bone Quality: Getting Closer to a Definition
Watts, N. B. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1148 · Cited by 75
Treatment of osteoporosis in chronic kidney disease and end-stage renal disease
Miller, P. D. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0021-y · Cited by 74
A FRAX® model for the assessment of fracture probability in Belgium
Johansson, H., Kanis, J. A., McCloskey, E. V., Odén, A., Devogelaer, J.-P., Kaufman, J., Neuprez, A., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1218-1 · Cited by 74
Self-citationEpstein, S. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.3.379 · Cited by 74
Cremers, S., Sparidans, R. W., den Hartigh, J., Hamdy, N. A. T., Vermeij, P., & Papapoulos, S. E. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0411-8 · Cited by 74
Lee, S., Glendenning, P., & Inderjeeth, C. A. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1335-x · Cited by 73
Eriksen, E. F. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9187-z · Cited by 74
Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
Gehrig, L. M. B., Lane, J., & O’Connor, M. I. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200806000-00028 · Cited by 73
Inhibition of bone turnover by milk intake in postmenopausal women
Bonjour, J., Brandolini-Bunlon, M., Boirie, Y., Morel-Laporte, F., Braesco, V., Bertiére, M.-C., & Souberbielle, J. (2008) · British Journal Of Nutrition · doi:10.1017/s0007114508937429 · Cited by 73
The Role of Bone Biopsy in Patients with Chronic Renal Failure
Miller, P. D. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02430508 · Cited by 73
Bishop, N. J., Harrison, R., Ahmed, S. F., Shaw, N., Eastell, R., Campbell, M., Knowles, E., Hill, C., Hall, C. M., Chapman, S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090712 · Cited by 72
Self-citationKamatari, M., Koto, S., Ozawa, N., Urao, C., Suzuki, Y., Akasaka, E., Yanagimoto, K., & Sakota, K. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0768-6 · Cited by 72
The use of raloxifenein osteoporosis treatment
D’Amelio, P., & Isaia, G. C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.782002 · Cited by 72
Quality of Life in Patients with Osteoporotic Vertebral Compression Fractures
Jung, H. J., Park, Y., Seo, H.-Y., Lee, J., An, K.-C., Kim, J.-H., Shin, B.-J., Kang, T. W., & Park, S.-Y. (2017) · Journal of Bone Metabolism · doi:10.11005/jbm.2017.24.3.187 · Cited by 72
Bauer, D. C., Black, D. M., Bouxsein, M. L., Lui, L.-Y., Cauley, J. A., de Papp, A. E., Grauer, A., Khosla, S., McCulloch, C. E., Eastell, R., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3355 · Cited by 71
Self-citationInderjeeth, C. A., Foo, A. C. H., Lai, M. M. Y., & Glendenning, P. (2008) · Bone · doi:10.1016/j.bone.2008.12.003 · Cited by 71
Glucocorticoid-induced osteoporosis
Clowes, J. A., Peel, N. F. A., & Eastell, R. (2001) · Current Opinion in Rheumatology · doi:10.1097/00002281-200107000-00015 · Cited by 71
Self-citationThe treatment gap: The missed opportunities for osteoporosis therapy
Fuggle, N. R., Curtis, E., Clynes, M. A., Zhang, J., Ward, K. A., Javaid, M. K., Harvey, N. C., Dennison, E. M., & Cooper, C. C. (2020) · Bone · doi:10.1016/j.bone.2020.115833 · Cited by 70
Lanza, F. L., Sahba, B., Schwartz, H., Winograd, S., Torosis, J., Quan, H., Reyes, R., Musliner, T., Daifotis, A. G., & LEUNG, A. T. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05446.x · Cited by 70
Sato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1737 · Cited by 69
RetractedGuyatt, G. H., Cranney, A., Griffith, L., Walter, S., Krolicki, N., Favus, M., & Rosen, C. (2002) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00024-5 · Cited by 69
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Hodsman, A. B., Hanley, D. A., & Josse, R. G. (2002) · Europe PMC (PubMed Central) · Cited by 69
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients
Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J. (2010) · Health Policy · doi:10.1016/j.healthpol.2010.01.014 · Cited by 68
Self-citationRisedronate reduces postoperative bone resorption after cementless total hip arthroplasty
Yamasaki, S., Masuhara, K., Yamaguchi, K., Nakai, T., Fuji, T., & Seino, Y. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0339-7 · Cited by 68
RETIRED: Osteoporosis in Menopause
Khan, A. A., Fortier, M. P., Fortier, M. P., Reid, R. L., Abramson, B. L., Blake, J. M., Desindes, S., Dodin, S., Graves, L. E., Guthrie, B., et al. (2014) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30489-8 · Cited by 68
RetractedMcCloskey, E. V., Johansson, H., Odén, A., & Kanis, J. А. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.05.001 · Cited by 67
Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study
Miller, P. D., Recker, R. R., Reginster, J.-Y., Riis, B. J., Czerwinski, E. J., Masanauskaite, D., Kenwright, A., Lorenc, R. S., Stakkestad, J. A., & Lakatos, P. L. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1773-0 · Cited by 67
Self-citationWhat is the optimal duration of bisphosphonate therapy?
Ott, S. M. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.11022 · Cited by 67
Bisphosphonates for post-menopausal osteoporosis: are they all the same?
Rizzoli, R. (2011) · QJM · doi:10.1093/qjmed/hcq259 · Cited by 67
Acute and long-term management of patients with vertebral fractures
Francis, R. M., BAILLIE, S. P., Chuck, A., Crook, P. R., Dunn, N., Fordham, J., Kelly, C. A., & Rodgers, A. (2004) · QJM · doi:10.1093/qjmed/hch012 · Cited by 67
Gold, D. T., Martin, B. C., Frytak, J. R., Amonkar, M. M., & Cosman, F. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167615 · Cited by 67
The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis
Genant, H. K., Halse, J., Briney, W. G., Xie, L., Glass, E. V., & Krege, J. H. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x49671 · Cited by 67
The causes and treatment of bone loss associated with carcinoma of the breast
LESTER, J., Dodwell, D. J., McCloskey, E. V., & COLEMAN, R. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.01.008 · Cited by 67
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results
Delmas, P. D., Benhamou, C. L., Man, Z., Tłustochowicz, W., Matzkin, E., Eusebio, R. A., Zanchetta, J., Olszynski, W. P., Recker, R. R., & McClung, M. R. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0531-9 · Cited by 67
Watts, N. B., Worley, K., Solis, A., Doyel, J., & Sheer, R. L. (2004) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2004.10.2.142 · Cited by 66
Hochberg, M. C. (2000) · Drugs & Aging · doi:10.2165/00002512-200017040-00007 · Cited by 66
Monitoring osteoporosis treatment
Compston, J. E. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.09.007 · Cited by 65
New approaches to pharmacological treatment of osteoporosis.
Åkesson, K. (2003) · Europe PMC (PubMed Central) · Cited by 65
For the MOVER Study Group, Nakamura, T., Nakano, T., Ito, M., Hagino, H., Hashimoto, J., Tobinai, M., & Mizunuma, H. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9734-6 · Cited by 65
Characterisation of Trabecular Bone Structure
Parkinson, I. H., & Fazzalari, N. L. (2012) · Studies in mechanobiology, tissue engineering and biomaterials · doi:10.1007/8415_2011_113 · Cited by 65
Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis
Raterman, H. G., Bultink, I. E. M., & Lems, W. F. (2019) · Drugs · doi:10.1007/s40265-019-01145-6 · Cited by 65
Malone, S., Perry, G., Segal, R., Dahrouge, S., & Crook, J. (2005) · BJU International · doi:10.1111/j.1464-410x.2005.05676.x · Cited by 61
Effects of bisphosphonates on osteoporosis: Focus on zoledronate
Oryan, A., & Sahvieh, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118681 · Cited by 64
van der Burgh, A. C., de Keyser, C. E., Zillikens, M. C., & Stricker, B. H. C. (2021) · Drugs · doi:10.1007/s40265-021-01625-8 · Cited by 64
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective
Borgström, F., Carlsson, Å., Sintonen, H., Boonen, S., Haentjens, P., Burge, R. T., Johnell, O., Jönsson, B., & Kanis, J. А. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0094-1 · Cited by 64
Prevrhal, S., Krege, J. H., Chen, P., Genant, H. K., & Black, D. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902790993 · Cited by 64
Dimai, H. P., & Fahrleitner‐Pammer, A. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101780 · Cited by 63
Treatment of primary osteoporosis in men
Bianchi, G., & Giusti, A. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s44057 · Cited by 63
Metadata
- Authors
- Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., & Eastell, R.
- Affiliations
- University of Liège (BE)
- The University of Sydney (AU)
- Hôpital Cochin (FR)
- University of Florence (IT)
- Procter & Gamble (United States) (US)
- University of Sheffield (GB)
- Venue
- Osteoporosis International
- Published
- 2000-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 83-91
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W1526826623
- Cited by
- 1,580
- References
- 29
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 25 · 2022: 26 · 2021: 31 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 27 · 2016: 44 · 2015: 50 · 2014: 47 · 2013: 69 · 2012: 66
- FWCI
- 78.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- risedronate, postmenopausal osteoporosis, vertebral fractures, fracture prevention, bisphosphonates, bone mineral density, non-vertebral fractures, calcium and vitamin D supplementation, gastrointestinal adverse effects, drug safety
- MeSH terms
- Risedronic Acid, Aged, Aged, 80 and over, Algorithms, Australia, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Middle Aged, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.